[{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$116.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces Closing of $116 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Oligonucleotide antibody","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$181.5 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces Closing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Entrada Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$735.0 million","upfrontCash":"$224.0 million","newsHeadline":"Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"EEV-conjugated Phosphorodiamidate Morpholino Oligomer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-45","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$735.0 million","upfrontCash":"$224.0 million","newsHeadline":"Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"EEV-conjugated Phosphorodiamidate Morpholino Oligomer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces $100 Million Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Janus Henderson Investors","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Janus Henderson Investors"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Reports Preliminary Data from Phase 1 ENTR-601-44-101 Trial for DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Entrada Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Entrada Therapeutics

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

02

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

03

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

04

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

05

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

06

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

07

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

08

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

09

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

10

Entrada Therapeutics

U.S.A

FNCE 2024

Not Confirmed

1
2